en · de · es · fr · pt
sr9009-notes.peptides9000.com › News › Background And Mechanism Of Sr9009 — Beginner to Advanced

Background And Mechanism Of Sr9009 — Beginner to Advanced

By Editorial Desk · published 2026-01-04 · last reviewed 2026-02-03 · News

This is a working overview of mitochondrial biogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Related pages on this site

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Handling Storage and Quality Control

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Reference notes

== Premise == FBI agents Cooper Madsen and Jordan Bennett investigate a series of unexplained deaths among international supermodels. Their inquiry leads to the discovery of a sexually transmitted virus called "The Beauty," which grants physical attractiveness but carries fatal consequences. As they trace its origins, the agents uncover a connection to a powerful and secretive tech figure known as "The Corporation," who seeks to protect the drug and its global expansion. Pursued by a hired operative known as "The Assassin," the agents continue their investigation across multiple international cities amid the growing outbreak.

John Bennett Fenn (June 15, 1917 – December 10, 2010) was an American analytical chemist who was awarded a share of the Nobel Prize in Chemistry in 2002, sharing half of the award with Koichi Tanaka for their work in mass spectrometry (the other half went to Kurt Wüthrich). His contributions related to the development of electrospray ionization, now a commonly used technique for large molecules and routine liquid chromatography-tandem mass spectrometry. Early in his career, he studied the field of jet propulsion at Project SQUID and focused on molecular beams. He finished his career with more than 100 publications, including one book. Fenn was born in New York City, and moved to Kentucky with his family during the Great Depression. Fenn did his undergraduate work at Berea College, and received his PhD from Yale. He worked in industry at Monsanto and at private research labs before moving to academic posts including Yale and Virginia Commonwealth University. Fenn's research into electrospray ionization found him at the center of a legal dispute with Yale University. He lost the lawsuit, after it was determined that he misled the university about the potential usefulness of the technology. Yale was awarded $500,000 in legal fees and $545,000 in damages. The decision pleased the university, but provoked mixed responses from some people affiliated with the institution, who were disappointed with the treatment of a Nobel Prize winner with such a long history at the school.

=== Global food distribution === Along with Archer Daniels Midland, Bunge, and Cargill, the Louis Dreyfus Company is one of the four "ABCD" companies that dominate world agricultural commodity trading.

=== Hoffman Instrumentation Supply Inc === In 2019, Hoffman Instrumentation Supply Inc was a component vendor to Edwards' US, subsidiary Edwards Vacuum LLC, and held talks about becoming exclusive supplier for some items. It was also proposed that Hoffman would construct subassemblies and complete systems, but only for Edwards. One of Hoffman's key customers enquired whether it could provide a vacuum system that would work with pumps other than Edwards'. Hoffman informed Edwards whose response was to suggest purchasing Hoffman. Information was provided about Hoffman to Edwards for due diligence, under a non disclosure agreement, in order to progress the acquisition. It included technical specifications for the pump agnostic vacuum system and Hoffman's cost structures. The parties did not agree terms to purchase Hoffman and Edwards withdrew from the process. A group of employees left Edwards to work for Hoffman and in 2020, Edwards sought an injunction against Hoffman to prevent misuse of the ex employees's trade secrets. Hoffman counter claimed Edwards used the confidential due diligence information to pitch their products to Hoffman's key customer at prices just below Hoffman's own intended level, and to demand cost reductions from suppliers to match those obtained by Hoffman.

Sources: en.wikipedia.org

Notes from published material

restriction map A diagram of known restriction sites within a known DNA sequence, such as a plasmid vector, obtained by systematically exposing the sequence to various restriction enzymes and then comparing the lengths of the resulting fragments, a technique known as restriction mapping. See also gene map.

An open-label pilot study on mild and moderate cases was performed in 2020, with mildly positive results. A phase III trial was performed in 2022 in China. In July 2022, China's drug regulator granted conditional approval for it to be used to treat COVID-19, following a local phase III trial. Initially, no detailed description of the said trial was published in any journals, but state media quoted some numbers from the developer: "40% clinical improvement in 7 days by FNC group, compared to 11% in control". It is unclear how such "improvement" is defined. Four phase III clinical trials investigated azvudine's efficacy and safety in adults with mild-to-moderate COVID-19. The findings indicate that azvudine may reduce the time to eliminate detectable levels of virus (viral load) and improve symptoms faster than standard treatment. In trials, it was reported to be safe with few side effects. However, some studies produced inconsistent results in terms of symptom improvement and severe illness prevention. Additionally, the studies tended to use a smaller number of participants than other major COVID-19 drug trials.

== Y == YAC (yeast artificial chromosome) - Ycf9 protein domain - YchF-GTPase C terminal protein domain - Ydc2 protein domain - YDG SRA protein domain - YecM bacterial protein domain - YjeF N terminal protein domain - YopH, N-terminal - YopR bacterial protein domain - Y Y Y -

Herophilos (335–280 BC) described the functions of the optic nerve in sight and the oculomotor nerve in eye movement. Analysis of the nerves in the cranium enabled him to differentiate between blood vessels and nerves (Ancient Greek: νεῦρον (neûron) "string, plant fiber, nerve"). Modern research has not confirmed William Cullen's 1785 hypothesis associating mental states with physical nerves, although popular or lay medicine may still invoke "nerves" in diagnosing or blaming any sort of psychological worry or hesitancy, as in the common traditional phrases "my poor nerves", "high-strung", and "nervous breakdown".

Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells. Because of its Class III antiarrhythmic activity, there should not be concomitant administration of Class Ia and Class III agents. Ibutilide is marketed as Corvert by Pfizer. Administration resulted in successful heart rhythm control in 31–44% of patients within 90 minutes, with sustained polymorphic ventricular tachycardia in 0.9–2.5% of patients. It appears to show better results in atrial flutter as compared to atrial fibrillation.

Sources: en.wikipedia.org

Background from the literature

===== Herpes zoster (chickenpox and shingles) ===== Varicella zoster is the virus responsible for chickenpox and shingles (also known as herpes zoster). The CDC advises that breastfeeding is safe to continue as long as the breasts are clear of lesions, also emphasizing that if pumping or hand expressing milk, proper hand-hygiene should be used to minimize transfer.

=== Aerosol === In aerosol mass spectrometry, one of the ionization techniques consists in firing a laser to individual droplets. These systems are called single particle mass spectrometers (SPMS). The sample may optionally be mixed with a MALDI matrix prior to aerosolization.

A nutrient is a substance used by an organism to survive, grow and reproduce. The requirement for dietary nutrient intake applies to animals, plants, fungi and protists. Nutrients can be incorporated into cells for metabolic purposes or excreted by cells to create non-cellular structures such as hair, scales, feathers, or exoskeletons. Some nutrients can be metabolically converted into smaller molecules in the process of releasing energy such as for carbohydrates, lipids, proteins and fermentation products (ethanol or vinegar) leading to end-products of water and carbon dioxide. All organisms require water. Essential nutrients for animals are the energy sources, some of the amino acids that are combined to create proteins, a subset of fatty acids, vitamins and certain minerals. Plants require more diverse minerals absorbed through roots, plus carbon dioxide and oxygen absorbed through leaves. Fungi live on dead or living organic matter and meet nutrient needs from their host. Different types of organisms have different essential nutrients. Ascorbic acid (vitamin C) is essential to humans and some animal species but most other animals and many plants are able to synthesize it. Nutrients may be organic or inorganic: organic compounds include most compounds containing carbon, while all other chemicals are inorganic. Inorganic nutrients include iron, selenium, and zinc, while organic nutrients include, protein, fats, sugars and vitamins. A classification used primarily to describe nutrient needs of animals divides nutrients into macronutrients and micronutrients.

Robin Carhart-Harris and Guy Goodwin write that the term psychedelic is preferable to hallucinogen for describing classical psychedelics because of the term hallucinogen's "arguably misleading emphasis on these compounds' hallucinogenic properties." While the term psychedelic is most commonly used to refer only to serotonergic hallucinogens, it is sometimes used for a much broader range of drugs, including entactogens, dissociatives, and atypical hallucinogens/psychoactives such as Amanita muscaria, Cannabis sativa, Nymphaea nouchali and Salvia divinorum. Thus, the term serotonergic psychedelic is sometimes used for the narrower class. It is important to check the definition of a given source. The present article uses the more common, narrower definition of psychedelic. David E. Nichols and Charles D. Nichols have criticized the expansion of the definition of the term psychedelic and called for it to continue to refer only to serotonergic psychedelics.

Lemonhead is an American brand of candy that was first introduced in 1962 and is produced by the Ferrara Candy Company. Lemonheads are a round, lemon flavored candy consisting of a sweet coating, a soft, sour shell, and a hard candy core. Inspiration for the Lemonhead name came from Salvatore Ferrara seeing his grandson, Salvatore II, after delivery. Salvatore II was a forceps baby and he noted that his new grandson's head was lemon shaped. The candy was born out of the same cold panned process as the company's Red Hots in 1962. In this process, layer after layer of sugar and flavor are added until the candy reaches the desired shape and size. They are most commonly sold in their standard 1 centimeter size, but they are also produced in a single-sale 3 cm version. Lemonhead candies are gluten and fat-free. Ferrara now makes 500 million Lemonheads per year. Some time between the 1980s and late 1990s, Ferrara Pan brought all of their fruit flavored candies under a consistent naming convention: Lemonheads, Grapeheads (formerly Alexander the Grape), Cherryheads (formerly Cherry Chan/Cherry Clan) and Appleheads (formerly Johnny Apple Treats). Today, only the standard Lemonhead variety remains.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network